Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 15 of 183 for:    Open Studies | "Analgesics"

Analgesic Effect of Oxytocin Receptor Modulation

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by University Hospital Inselspital, Berne
Sponsor:
Information provided by (Responsible Party):
University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier:
NCT01918475
First received: August 6, 2013
Last updated: September 29, 2014
Last verified: September 2014
  Purpose

Carbetocin is a synthetic analogue of the hormone Oxytocin and is routinely used in obstetric anesthesiology to control uterine bleeding after cesarean section. As an incidental finding, women who received carbetocin had less pain after cesarean section than women who had received Oxytocin. Carbetocin may therefore have an analgesic effect.

The present study examines this analgesic effect using different sensory tests, e.g. pressure, heat, cold and electrical pain before and after administration of carbetocin in healthy male volunteers. Any changes in these sensory tests might be indicative of an analgesic property of carbetocin.


Condition Intervention
Pain
Hyperalgesia
Central Sensitization
Drug: Carbetocin
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by University Hospital Inselspital, Berne:

Primary Outcome Measures:
  • Change in intramuscular electrical pain threshold compared to baseline [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Capsaicin-induced area of hyperalgesia and allodynia [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]
  • Nociceptive withdrawal reflex thresholds of the foot [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]
  • Single cutaneous electrical pain thresholds [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]
  • Repeated cutaneous electrical pain thresholds [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]
  • Single intramuscular electrical pain threshold [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]
  • Heat pain detection threshold [ Time Frame: 10, 60 and 120 minutes after carbeoticin administration ] [ Designated as safety issue: No ]
  • Heat pain tolerance threshold [ Time Frame: 10, 60 and 120 minutes after carbetocin administration ] [ Designated as safety issue: No ]

Estimated Enrollment: 25
Study Start Date: July 2013
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Carbetocin first
Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
Drug: Carbetocin
Carbetocin 0.1 mg single dose is intravenously administered
Drug: Placebo
1ml of NaCl 0.9% is administered intravenously
Active Comparator: Placebo first
Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
Drug: Carbetocin
Carbetocin 0.1 mg single dose is intravenously administered
Drug: Placebo
1ml of NaCl 0.9% is administered intravenously

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • male
  • pain-free
  • written informed consent

Exclusion Criteria

  • chronic pain
  • acute pain at time of testing
  • sign or suspicion of neurological dysfunction at the tested sites
  • intake of opioids
  • intake of benzodiazepines
  • intake of antidepressants
  • intake of anticonvulsants
  • intake of any analgesic drug 48h prior to test
  • known allergy to carbetocin
  • allergy to capsaicin
  • cardiovascular disease
  • asthma bronchiale
  • migraine
  • epilepsy
  • history of liver disease
  • history of renal disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01918475

Contacts
Contact: Jürg Schliessbach, M.D: 031 632 21 11 juerg.schliessbach@insel.ch

Locations
Switzerland
University Department of Anesthesiology and Pain Therapy, Bern University Hospital Recruiting
Bern, Switzerland, 3010 Bern
Contact: Jürg Schliessbach, M.D.    031 632 21 11    juerg.schliessbach@insel.ch   
Principal Investigator: Pascal Vuilleumier, M.D.         
Sub-Investigator: Jürg Schliessbach, M.D.         
Sub-Investigator: Ulrike Stamer, M.D.         
Sponsors and Collaborators
University Hospital Inselspital, Berne
Investigators
Study Chair: Michele Curatolo, M.D., Ph.D. University Department of Anesthesiology and Pain Therapy, Inselspital Bern, Switzerland
  More Information

Publications:
Responsible Party: University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier: NCT01918475     History of Changes
Other Study ID Numbers: 140/12, 2013DR1021
Study First Received: August 6, 2013
Last Updated: September 29, 2014
Health Authority: Switzerland: Ethikkommission
Switzerland: Swissmedic

Keywords provided by University Hospital Inselspital, Berne:
randomized controlled trial
placebo controlled trial
cross over trial

Additional relevant MeSH terms:
Hyperalgesia
Nervous System Diseases
Neurologic Manifestations
Sensation Disorders
Signs and Symptoms
Somatosensory Disorders
Analgesics
Carbetocin
Central Nervous System Agents
Oxytocics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 23, 2014